Assessment of Cytomegalovirus Hybrid Preventative Strategy in Pediatric Heart Transplant Patients.

Autor:	Lin A; Case Western Reserve University School of Medicine, Cleveland., Worley S; Department of Quantitative Health Sciences, Cleveland Clinic, and., Brubaker J; Department of Pediatric Cardiology, Pediatric Institute and The Children's Hospital at Cleveland Clinic;, Boyle G; Department of Pediatric Cardiology, Pediatric Institute and The Children's Hospital at Cleveland Clinic;, Nasman C; Department of Pediatric Cardiology, Pediatric Institute and The Children's Hospital at Cleveland Clinic;, Sabella C; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Ohio., Danziger-Isakov LA; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Ohio danzigl@ccf.org.
Jazyk:	angličtina
Zdroj:	Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2012 Dec; Vol. 1 (4), pp. 278-83. Date of Electronic Publication: 2012 Jul 12.
DOI:	10.1093/jpids/pis056
Abstrakt:	Background: Prevention strategies for cytomegalovirus (CMV) in pediatric transplant recipients are sparsely reported. A hybrid strategy that combines prophylaxis with preemptive therapy using serial CMV viral load monitoring is an emerging option. We report our clinical outcomes with a hybrid strategy in pediatric heart transplant recipients. Methods: A retrospective chart review was performed for pediatric heart transplant recipients who received a hybrid strategy of 2-4 weeks intravenous ganciclovir followed by serial whole blood CMV monitoring from 2002 to 2010. Subject demographics, medications, drug levels, serial CMV viral loads, intravascular ultrasound and angiography reports, and histopathology were collected. Descriptive statistics and patient groups were compared using χ(2), Fisher's exact, and Wilcoxon rank-sum tests. Results: Twelve females and 13 males, ranging from 4 months to 19 years of age, underwent 26 heart transplants. Mean follow-up was 39 months (range, 5-94 months). Fourteen (54%) subjects were CMV donor (D) + /recipient (R) - , 8 (31%) were D + /R + , and 4 (15%) were D - /R + . Six subjects (23%) died of complications unrelated to CMV. Median prophylaxis duration was 25 days (range, 7-70 days). Ten (38%) subjects developed CMV infection: 1 subject had 2 episodes of CMV syndrome, and 1 subject had 2 episodes CMV. Although 6 of 14 patients with coronary artery vasculopathy had prior CMV, no association was found (P = .81). Median time to first CMV DNAemia was 2.3 months (range, 9 days to 24.8 months). Median time to viral load clearance was 29 days (range, 4-233 days). In addition, 25 D - /R- patients were transplanted and received no prophylaxis; 2 (8%) patients developed CMV infection. Conclusions: Pediatric heart transplant recipients who were at risk for CMV and treated with a novel preventative hybrid strategy developed CMV infection, syndrome, and disease at rates similar to those reported in literature for prophylactic strategies. (© The Author 2012. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu